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Introduction: Bortezomib is a proteasome inhibitor used in the treatment of multiple myeloma. A newly
recognized oculomotor nerve palsy related to bortezomib is described.
Case presentation: A 54-year-old Caucasian woman with immunoglobulin G kappa multiple myeloma on
single-agent bortezomib given by intravenous push once weekly developed isolated unilateral partially reversible
left sided oculomotor nerve palsy during the first cycle of treatment. All the essential diagnostic tests that were
carried out excluded all other possible causes. There was a positive dechallenge-rechallenge test. Management was
by withdrawal of bortezomib and empirical dexamethazone. To the best of our knowledge, this is the first report
of its kind in the literature.
Conclusion: This case illustrates the probable association between oculomotor nerve palsy and bortezomib, and
generates a hypothesis of whether bortezomib can cross the blood-brain barrier or not.
Introduction
Bortezomib is a 26S proteasome inhibitor which acti-
vates signaling cascades, cell cycle arrest and apoptosis.
Intravenous bortezomib is a recommended treatment in
multiple myeloma, as demonstrated in the phase II
CREST and SUMMIT trials, and the phase III APEX
trial. Most of the reports regarding neurologic adverse
events of bortezomib relate to associated peripheral neu-
ropathy. None reported associated cranial neuropathies.
We are reporting this adverse event to describe a newly
recognized possible adverse reaction or interaction
related to bortezomib which is oculomotor nerve palsy.
To the best of our knowledge, this is the first report of
this kind in the literature.
Case presentation
A 54-year-old Caucasian woman had a positive family
history for hypertension and negative family history for
malignancy, with hypertension controlled by enalapril
and atenolol and open angle glaucoma controlled by
latanoprost eye drops. She was diagnosed with immuno-
globulin G kappa multiple myeloma and started borte-
zomib as a first line therapy for multiple myeloma. She
received bortezomib as a single agent (1.3 mg/m
2;t o t a l
dose of 2 mg) via intravenous push once weekly for
multiple myeloma. The treatment regimen was given in
a non standard way without concomitant dexametha-
zone. She received Cycle 1 Day one, Cycle 1 Day eight,
C y c l e1D a y1 5a n dd e v e l o p e di solated unilateral par-
tially reversible left sided oculomotor nerve palsy on
Cycle 1 Day 21.
The developed isolated unilateral partially reversible
left sided oculomotor nerve palsy was graded as II
according to National Cancer Institute’s Common Toxi-
city Criteria Version 2.0, as there was partial weakness
of levator palpebrae muscle power resulting in mild par-
tial ptosis of the left eye and persistent impairment of
the third nerve mediated extraocular muscle movement.
This resulted in complete loss of medial movement
‘adduction’ of left eye, divergent squint and partially
defective upward ‘elevation’ and downward ‘depression’
movement of the left eye. The objective weakness is
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any medium, provided the original work is properly cited.mild, interfering with function, but not interfering with
activities of daily living.
Management of this adverse drug event was by with-
drawal of the drug bortezomib by omitting Cycle 1
week four (Day 22) of bortezomib and replacing it with
an intravenous infusion of dexamethazone (8 mg) once
d a i l yf o rf o u rd a y so nC y c l e1D a y2 2 ,C y c l e1D a y2 3 ,
Cycle 1 Day 24 and Cycle 1 Day 25. On Cycle 1 Day 27
good partial improvement of the oculomotor nerve
palsy was noted and therefore Cycle 2 Day one of borte-
zomib was given. On Cycle 2 Day three there was strong
reappearance of most of the signs of left sided oculomo-
tor nerve palsy and despite reintroducing a dexametha-
zone 8 mg intravenous infusion once daily for four days
on Cycle 2 Day four, Cycle 2 Day five, Cycle 2 Day six
and Cycle 2 Day seven to ameliorate the signs of oculo-
motor nerve palsy, yet the response noted was not as
striking as before and the improvement was nil leaving
our patient with residual oculomotor nerve palsy. Even-
tually bortezomib was discontinued and our patient
shifted to melphalan-lenalidomide combination therapy.
Discussion
The case presented here showed suggestive evidence
linking the drug to the event. To associate bortezomib
to the oculomotor nerve palsy, we had to rule out all
other possible causes, assess the temporal relationship
and pharmacological time plausibility, and confirm posi-
tive dechallenge/rechallenge response.
Our patient’s only known comorbidities are hyperten-
sion of ten years duration controlled by enalapril and
atenolol, and open angle glaucoma of two months dura-
tion controlled by latanoprost eye drops. These three
medications (enalapril tablets, atenolol tablets and lata-
noprost eye drops) are not reported to cause oculomo-
tor nerve palsy or any other similar cranial nerve palsy
or neuropathy. Furthermore, she had used enalapril
tablets and atenolol tablets for ten years and latanoprost
eye drops for two months without developing this
adverse event. She has no past history of any cerebro-
vascular accident or any thromboembolic event. She is
not known to be diabetic and not known to suffer from
peripheral vascular disease. She never complained of any
similar incident of cranial nerve palsy or even peripheral
neuropathy.
Fundoscopy was carried out and it showed the optic
disc to be within normal appearance, no papilloedema
was detected. A beta scan of both eyes was done and
showed bilateral normal retinochoroidal thickness and
bilateral normal optic nerve thickness.
Magnetic resonance imaging (MRI) of the brain and
brain stem with and without contrast was carried out
and the only finding was a focal enhancing area in the
white matter of the right pons about 11 mm in
maximum diameter with low T1 and high T2 signal.
This area showed diffuse enhancement in the post con-
trast study and there is no surrounding edema detected.
This was graded as a non-specific appearance and differ-
ential diagnosis includes demyelination and minute cere-
brovascular accident. A decision was taken not to follow
this non-specific lesion by a repeat MRI of the brain
and brain stem since this lesion is right sided and
usually left oculomotor nerve palsy is expected to occur
by an ipsilateral structural lesion on the same side.
Cerebrospinal fluid (CSF) was obtained by lumbar
puncture. Cytological examination of the CSF sample
was negative for malignant cells. An analysis and cell
count of the CSF sample showed negative criteria for
subarachnoid hemorrhage, multiple sclerosis and/or
viral and bacterial meningitis. Glucose level in the CSF
sample was 4.4 mmol/L (reference range: 2.2 to 3.9), the
protein level in the CSF sample was 440 mg/L (refer-
ence range: 120 to 600). The CSF sample total volume
was 1.3 mL, with clear appearance and was colorless,
white blood cell count in the sample was three cells per
microliter (reference range: zero to five) and red blood
cell count in the sample was zero cells per microliter
(reference range: zero to five). CSF culture and sensitiv-
ity showed no growth after 72 hours of incubation and
no growth after enrichment culture.
Nerve conduction studies were not done because
although our patient complained of numbness and per-
ipheral paraesthesia, they were mild and did not inter-
fere with the activities of daily living.
Despite the CSF cytology being negative for malignant
cells and a MRI of the brain being inconclusive, it is
impossible to rule out with 100% certainty extramedul-
lary myelomatous infiltration of the brain. The only
point that suggests that this adverse event wasn’t related
to multiple myeloma was that the serial serum IgG level
which was used as a biomarker to follow the status of
her disease was dropping from baseline of 53.4 g/L
before initiation of the bortezomib to 23.5 g/L on the
day she developed this adverse event meaning that her
disease was responding to bortezomib.
This is a plausible collateral adverse event that
occurred early as regards time onset. Our patient was
on bortezomib (1.3 mg/m
2; total dose of 2 mg) as a first
line monotherapy that was administered as intravenous
push once weekly, she received Cycle 1 week 1 (Day
one), Cycle 1 week two (Day eight), Cycle 1 week three
(Day 15) and developed the adverse event on Cycle 1
Day 21. According to the DoTS classification, this is
probably a collateral effect of early persistent or inter-
mediate time-course; the susceptibility factors are not
known [1].
To the best of our knowledge, there has been no pre-
viously reported or published recognized association
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(cranial neuropathy) with the product ‘bortezomib’ or
the class ‘proteasome inhibitor’. There have been several
reports of peripheral neuropathies with the product
‘bortezomib’ or the class ‘proteasome inhibitor’.
Plasma level of bortezomib or its metabolite was not
assessed at the time of the adverse event.
There is insufficient animal and in vitro data regarding
the association of cranial nerve palsy with bortezomib as
a possible adverse event related to the drug.
Omitting Cycle 1 week four (Day 22) of bortezomib
resulted in partial improvement of the signs of oculomo-
tor nerve palsy. Partial improvement was noticed on
Cycle 1 Day 27 i.e. after five days of omitting the dose
of bortezomib.
Giving cycle 2 week one (Day one) of bortezomib
resulted in reappearance of most of the signs of left
sided oculomotor nerve palsy after 48 to 72 hours of
reintroducing bortezomib.
Conclusion
This is a case report of a single patient. The drug impli-
cated is bortezomib. There is probably a true association
linking oculomotor nerve palsy to bortezomib (score of
7 according to Naranjo algorithm). Some suggested rea-
sons are the temporal relationship and pharmacological
time plausibility, positive dechallenge/rechallenge and all
other possible causes for oculomotor nerve palsy were
ruled out.
The hypothesis generated is: does bortezomib cross
the blood-brain barrier or not and can bortezomib
cause cranial neuropathy or not? There are no relevant
published pharmacokinetic studies regarding the ability
of bortezomib to cross the blood-brain barrier. Further
observational studies are warranted.
The mechanism for this adverse drug event is not
known. It is proposed to be either direct neurotoxicity
of bortezomib or modulation of the inflammatory and
immune responses via affecting function and survival
of immune cells such as lymphocytes and dendritic
cells [2]. The effect of bortezomib may be similar to
that of immunosuppressive or immunomodulating
agents, such as cyclosporin, tumor necrosis factor alpha
antagonists (infliximab, etanercept, adalimumab), or to
that of autologous peripheral blood stem cell transplan-
tation, which have all been reported to precipitate both
acute and chronic inflammatory demyelinating neuropa-
thies [3-6]. In case of the associated neuropathy of
tumor necrosis factor alpha antagonists, the possible
mechanisms of action include both T-cell and humoral
immune attack against peripheral nerve myelin, vasculi-
tis-induced nerve ischemia, and inhibition of signaling
support for axons [7].
The implications for clinical practice include that
patients should undergo a standard neurological exami-
nation before starting bortezomib, and close clinical fol-
low-up should be assured to reduce dosage or
discontinue bortezomib in the case of the appearance,
persistence or worsening of neurological symptoms.
Should the neurological impairment worsen despite bor-
tezomib dose reduction or discontinuation, the adminis-
tration of an immune treatment such as steroids or
intravenous immunoglobulins may be considered,
assuming that most likely underlying mechanism is
immune-mediated neuropathy [8].
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